Your browser is no longer supported. Please, upgrade your browser.
Aligos Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.40 Insider Own18.91% Shs Outstand37.74M Perf Week6.43%
Market Cap700.08M Forward P/E- EPS next Y-3.19 Insider Trans0.00% Shs Float32.89M Perf Month3.61%
Income-125.20M PEG- EPS next Q-0.81 Inst Own75.50% Short Float5.78% Perf Quarter5.41%
Sales2.50M P/S280.03 EPS this Y-109.30% Inst Trans8.96% Short Ratio8.95 Perf Half Y-35.33%
Book/sh4.47 P/B3.66 EPS next Y-3.60% ROA-62.30% Target Price34.75 Perf Year10.68%
Cash/sh4.46 P/C3.67 EPS next 5Y- ROE-111.90% 52W Range13.30 - 37.51 Perf YTD-40.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.33% Beta-
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low23.16% ATR0.86
Employees86 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)59.75 Volatility5.44% 6.00%
OptionableYes Debt/Eq0.00 EPS Q/Q28.60% Profit Margin- Rel Volume0.47 Prev Close16.19
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume212.44K Price16.38
Recom1.60 SMA207.93% SMA504.84% SMA200-24.72% Volume100,725 Change1.17%
Sep-09-21Initiated SVB Leerink Outperform $29
May-17-21Resumed Piper Sandler Overweight $47
Nov-10-20Initiated Piper Sandler Overweight $35
Nov-10-20Initiated JP Morgan Overweight $33
Nov-10-20Initiated Jefferies Buy $26
Nov-10-20Initiated Cantor Fitzgerald Overweight $28
Oct-20-21 06:02AM  
Oct-14-21 04:58PM  
Oct-11-21 08:00AM  
Sep-20-21 04:05PM  
Aug-05-21 04:05PM  
Jul-29-21 04:05PM  
Jul-06-21 01:37AM  
Jun-30-21 10:08PM  
Jun-28-21 04:10PM  
Jun-21-21 08:00AM  
Jun-14-21 08:00AM  
Jun-10-21 07:00AM  
May-20-21 04:05PM  
May-10-21 04:05PM  
May-05-21 08:00AM  
Apr-27-21 04:01PM  
Apr-14-21 08:00AM  
Mar-23-21 04:05PM  
Mar-10-21 08:00AM  
Mar-08-21 08:00AM  
Feb-03-21 08:00AM  
Jan-16-21 01:06AM  
Jan-07-21 08:00AM  
Dec-17-20 08:00AM  
Dec-07-20 08:00AM  
Nov-18-20 10:48AM  
Nov-16-20 08:00AM  
Nov-13-20 08:00AM  
Nov-12-20 08:00AM  
Oct-30-20 08:00AM  
Oct-23-20 06:00PM  
Oct-16-20 06:05PM  
Oct-15-20 10:19PM  
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR- agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.